Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 21, Issue 5, Pages 525-530Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2009.07.015
Keywords
-
Categories
Funding
- Leukemia and Lymphoma Society
- Italian Association for Cancer Research
- Italian Ministry of Further Education
- Italian Ministry of Health
- European Community Framework Programme 6 [LSHB-CT-2004-503319]
- National Institutes for Health of the USA [1 PO1 CA100265]
- Leukemia & Lymphoma Society Special Fellow
- NATIONAL CANCER INSTITUTE [P01CA100265] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Donor-versus-recipient natural killer (NK) cell alloreactivity has been established as a key therapeutic element in HLA haplotype mismatched hematopoietic transplants in adult AML and pediatric ALL and as a possible beneficial effector in cord blood transplant for AML. It is effected by functional NK cells which express inhibitory killer cell immunoglobulin-like receptor(s) (KIR) for self-class I ligand(s), sense missing expression of donor KIR ligand(s) in the recipient and mediate alloreactions. At present NK cell allotherapy for leukemia is deployed through stem cell transplantation (and ensuing NK cell reconstitution) across KIR ligand mismatches. Studies have been performed to infuse NK cells for immunotherapy outside the fields of transplantation and/or harness the function of endogenous NK cells in patients with hematological malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available